Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

When you get a van insurance quote you need to choose a class of use. You should select the class of use according to how you use your van. Here's what you need to know about the meaning of classes of ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

A lawsuit filed by three former employees of Bellflower St. John Bosco High alleges that highly decorated football coach Jason Negro embezzled money from the Catholic school for years and had ...

In 1889, Vincent van Gogh committed himself to a psychiatric asylum in Southern France, where he spent a turbulent year creating roughly 150 paintings, including masterpieces such as “Irises ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...